This site is part of the Siconnects Division of Sciinov Group

This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.

ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR

Registration
Event
Hybrid Event

Accelerate Ideas, Partnerships and Opportunities

Book your SLOT NOW
  • Start 9:00am - 6:00pm
  • Dubai, UAE
 

About Conference

Sciinov Group is proud to announce the Oligonucleotide Therapeutics and Delivery Conference, 10-11 November, 2025 in Dubai, UAE. This year OTDC 2025 annual Oligonucleotide Therapeutics and Delivery conference will showcase recent advances in oligonucleotide development, regulatory requirements and CMC considerations, strategies to enhance oligonucleotide discovery and targeting and optimised delivery techniques for oligonucleotide-based therapies, in the hope to continue to drive forward the field of oligonucleotide drug development. Join us on the 11 November, 2025 at Dubai, UAE.


Industry and academic experts deliver detailed case studies on antisense, RNA, GalNAc, aptamers, conjugates and other ne...

Readmore

Author's Login
Abstract Tracking Tool

ask & questions

answer

We are always looking for new industry leaders to join our speaker faculty to deliver presentations, lead panel discussions and moderate sessions or roundtables. 
If you are interested in being considered as a speaker, submit your proposal/abstract Online

answer

We let speakers propose the topic they want to talk about. This process allows speakers to propose sessions that speak from their expertise and passion.
Speaker can choose the topic of your choice in related to the conference subject or any of their recent research work to present at our conference.
For details of scientific sessions covered please visit [not limited to, you can propose]  

 

answer

Please visit the page here

answer

Yes, as our conference is scheduled in Hybrid Mode, you can present and listen to full program virtually connecting via ZOOM live stream


Recent Updates

21 Feb
2025

Groundbreaking study shows potential of new mRNA vaccine to help fight tuberculosis

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials, as part of a successful collaboration between three leading Australian research institutions. Readmore

27 Feb
2025

An ancient RNA-guided system could simplify delivery of gene editing therapies

A vast search of natural diversity has led scientists at MIT’s McGovern Institute for Brain Research and the Broad Institute of MIT and Harvard to uncover ancient systems with potential to expand the genome editing toolbox. Readmore

11 Mar
2025

Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines

Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, today announced it entered into a Research Collaboration and Option Agreement with Daiichi SankyoReadmore

14 Mar
2025

RPI Researchers Aim to Manufacture mRNA More Affordably

A sponsored research agreement with BioNTech will fund a project that aims to improve the mRNA manufacturing processReadmore


08:00-09:00

Registration

09:00-09:30

Opening Ceremony and Introduction

09:30-10:10

Keynote Session I

10:10-10:50

Keynote Session II

10:50-11:00

Refreshment Break

11:00-15:00

Break Out Session I

15:00-15:10

Refreshment Break

15:10-18:00

Break Out Session II

09:30-10:10

Keynote Session III

10:10-10:50

Keynote Session IV

10:50-11:00

Refreshment Break

11:00-15:00

Break Out Session III

15:00-15:10

Refreshment Break

15:10-18:00

Break Out Session IV

Get more information

make a booking now

Market Reports

Subscribe to our News & Updates